07829086 is referenced by 17 patents and cites 32 patents.

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

Title
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
Application Number
11/715308
Publication Number
7829086 (B2)
Application Date
March 6, 2007
Publication Date
November 9, 2010
Inventor
David G Williams
Epsom
GB
Tarran Jones
Radlett
GB
David M Hilbert
Bethesda
MD, US
Agent
Jones Day
Assignee
Aeres Biomedical
GB
Medimmune
MD, US
IPC
C07H 21/04
C07K 16/18
A61K 39/395
View Original Source